Methicillin-resistant staphylococcus aureus therapy: Past, present, and future

Clinical Infectious Diseases

Volumn 58, Issue SUPPL. 1, 2014, Pages

  Rodvold, Keith A ^a   Mcconeghy, Kevin W ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 84892143010     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit614     Document Type: Article

References (54)

1. Moellering RC Jr. MRSA: The first half century. J Antimicrob Chemother 2012; 67:4-11
2. Gould IM, David MZ, Esposito S, et al. New insights into meticillinresistant Staphylococcus aureus pathogenesis, treatment and resistance. Int J Antimicrob Agents 2012; 39:96-104
3. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55
4. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12
5. Shaw KJ, Barbachyn MR. The oxazolidinones: Past, present, and future. Ann NY Acad Sci 2011; 1241:48-70
6. Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care 2009; 15:403-12
7. Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: Is combination therapy the answer? J Antimicrob Chemother 2010; 65: 24-36
8. Schilling A, Neuner E, Rehm SJ. Vancomycin: A 50-something-yearold antibiotic we still don't understand. Cleve Clin J Med 2011; 78: 465-71
9. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection cause by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536-42
10. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus: An antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543-8
11. Yang Y, McBride MV, Rodvold KA, et al. Hospital policies and practices on prevention and treatment of infections caused by methicillin- resistant Staphylococcus aureus. Am J Health-Syst Pharm 2010; 67: 1017-24
12. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71
13. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008; 32: 378-85
14. Aguado JM, San-Juan R, Lalueza A, et al. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis 2011; 17:1099-102
15. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-7
16. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chemother 2011; 66:2386-92
17. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: Support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-81
18. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: We can't get there from here. Clin Infect Dis 2011; 52: 969-74
19. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: A critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37:95-101
20. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000; 46:775-84
21. Campbell ML, Marchaim D, Pogue JM, et al. Treatment of methicillinresistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: Old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother 2012; 46(12):1587-97
22. Goldberg E, Paul M, Talker O, et al. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: A retrospective cohort study. J Antimicrob Chemother 2010; 65: 1779-83
23. Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Ann NY Acad Sci 2011; 1222:49-54
24. Zyvox (linezolid) [package insert]. New York, NY: Pharmacia and Upjohn Co, Division of Pfizer Inc, revised 2012
25. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin Infect Dis 2012; 54:621-9
26. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013; 68:4-11
27. Sánchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260-4
28. Schriever CA, Fernández C, Rodvold KA, Danziger LH. Daptomycin: A novel cyclic lipopeptide antimicrobial. Am J Health-Syst Pharm 2005; 62:1145-58
29. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65
30. Moore CK, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: A case-control study. Clin Infect Dis 2012; 54:51-8
31. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: Facts and assumptions. Lancet Infect Dis 2009; 9:617-24
32. Cubicin (daptomycin) [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc, 2012
33. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase levels: Data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50:1568-74
34. Slover CM, Rodvold KA, Danziger LH. Tigecycline: A novel broad-spectrum antimicrobial. Ann Pharmacother 2007; 41:965-72
35. US Food and Drug Administration. FDA Drug Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010. Available at: Http:// www.fda.gov/Drugs/ DrugSafety/ucm224370.htm. Accessed 7 November 2012
36. Cai Y,Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55:1162-72
37. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis. Lancet Infect Dis 2011; 11:834-44
38. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: A systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1963-71
39. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699-709
40. Vardakas KZ, Mavros MN, Roussos N, Falagas ME. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: Focus on the study design. Mayo Clin Proc 2012; 87:349-63
41. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221-9
42. Vibativ (telavancin) [package insert]. Deerfield, IL: Astellas Pharma US, Inc., 2009
43. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31-40
44. Theravance reports favorable outcome of FDA advisory committee meeting on VIBATIV (telavancin) for the treatment of nosocomial pneumonia [press release]. Theravance Inc, 2012. http://investor. theravance.com/releasedetail.cfm? releaseid=724135. Accessed 19 December 2012
45. Lodise TP, Low DE. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 2012; 72:1473-93
46. File TM Jr,Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012; 55(Suppl 3): S173-80
47. Moellering RC Jr. Discovering new antimicrobial agents. Int J Antimicrob Agents 2011; 37:2-9
48. Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann NY Acad Sci 2011; 1241:122-52
49. Echols RM. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world. Ann NY Acad Sci 2011; 1241:153-61
50. Infectious Diseases Society of America. The 10×'20 initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50:1081-3
51. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H; on behalf of the CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: Update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis 2012; 55: 1114-21
52. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: Oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010; 30: 80-94
53. Jabes D. The antibiotic R&D pipeline: An update. Curr Opin Microbiol 2011; 14:564-9
54. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Draft Guidance [monograph]. 2010. Clinical/antimicrobial revision 1. Available at: Http:// www.fda.gov/downloads/ Drugs/.../Guidances/ucm071185.pdf. Accessed 31 October 2012